Drugs / 5A peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04216342 | Sep 2021 → Jun 2027 expected | cardiovascular disorder | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5A peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04216342 ↗ |
| Known as | peptide 5A | “referred to as the 5A peptide (or peptide 5A)” NCT04216342 ↗ |
| Modality | Peptide | “a short synthetic peptide mimic of Apolipoprotein A-I (apoA-I)” NCT04216342 ↗ |
| Route | Intravenous | “a single intravenous infusion of the Fx-5A peptide-lipid complex” NCT04216342 ↗ |
| Target | ABCA1 | “Fx-5A was specifically designed to remove excess cellular cholesterol via the ABCA1 transporter” NCT04216342 ↗ |